Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | BRAF | P15056 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.58 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | PIR | O00625 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | STK16 | O75716 | 1/20 | 0.53 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | FES | P07332 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298152 | 1.00 | CYP3A4 (0.67) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL299089 | 0.93 | CYP3A4 (0.64) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL298516 | 0.88 | BRAF (0.68) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL298723 | 0.87 | CYP2C9 (0.71) | CYP3A4BRAFCYP2C9CYP2C19 | |
| SCHEMBL299212 | 0.87 | CYP2C19 (0.68) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL12472431 | 0.87 | BRAF (0.61) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL413374 | 0.87 | BRAF (0.67) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL298200 | 0.86 | CYP3A4 (0.73) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL287878 | 0.85 | BRAF (0.59) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B | |
| SCHEMBL10247613 | 0.85 | BRAF (0.59) | CYP3A4BRAFCYP2C9CYP2C19BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP3A4 1288/4885BRAF 1608/4885CYP2C9 871/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP3A4 1288/4885BRAF 1608/4885CYP2C9 871/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP3A4 1288/4885BRAF 1608/4885CYP2C9 871/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | CYP3A4 3203/4885BRAF 1048/4885CYP2C9 4092/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP3A4 1288/4885BRAF 1608/4885CYP2C9 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.